Lipid-Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long-Term Experience in a Large Group of Patients with Hypercholesterolemia

This publication has 25 references indexed in Scilit:

• Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients
  The American Journal of Cardiology, 1998
• Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
  Circulation, 1998
• Dietary Guidelines for Healthy American Adults
  Circulation, 1996
• Efficacy and Safety of a New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients With Hypertriglyceridemia
  JAMA, 1996
• Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A Reappraisal
  Drug Safety, 1996
• Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia
  Clinical Cardiology, 1995
• Cholesterol Reduction Yields Clinical Benefit
  Circulation, 1995
• Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
  The Lancet, 1994
• Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.
  Circulation, 1992
• Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
  Archives of internal medicine (1960), 1991